Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 40%Very low 0 · 0%Low 3 · 60%Moderate 0 · 0%High 0 · 0%

Varenicline vs nicotine replacement therapy monotherapy

Neuropsychiatric SAEs · people who smoke

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 137 participants
GRADE not reported

Varenicline vs combination nicotine replacement therapy

Neuropsychiatric SAEs · people who smoke

Varenicline showed no clear difference in neuropsychiatric SAEs compared with combination nicotine replacement therapy (low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 4.69 [0.23, 96.5]
2 studies · 764 participants
Low

Varenicline vs bupropion

Neuropsychiatric SAEs · people who smoke

Varenicline showed no clear difference in neuropsychiatric SAEs compared with bupropion (low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 1.05 [0.16, 7.04]
2 studies · 866 participants
Low

Varenicline vs e‐cigarettes

Neuropsychiatric SAEs · people who continued to smoke tobacco following acute coronary syndrome

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
GRADE not reported

Varenicline vs placebo or no medication

Neuropsychiatric SAEs · people who smoke

Varenicline showed no clear difference in neuropsychiatric SAEs (varenicline vs placebo or no medication) compared with placebo or no medication (low certainty).

1 finding from 1 review

Nicotine receptor partial agonists for smoking cessation 2023 · Cochrane Headline outcomes only
RR 0.89 [0.61, 1.29]
22 studies · 7846 participants
Low